Cite

    Mark A Boyd et al.. “Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.” Lancet, vol. 4, no. 1, 2017, pp. e13–e20. http://access.bl.uk/ark:/81055/vdc_100040771514.0x000007